Skip to main content

I Am Done With Coronamonomania, Part 5

By April 27, 2024Commentary

The first three studies reported all deal with children and the epidemic.

Here is an awful study from California, claims that vaccinating children avoided a high number of cases and a small number of hospitalizations.  But it is basically a made-up model using other age groups.  No direct control groups, and once more, no consideration of prior infection status.  Astounding to me that people are still working hard to make up results to justify vaxing kids, who had basically no risk.  (JAMA Article)

Let’s see, here is great logic from the CDC–the CV-19 vaccines don’t work very well in children and adolescents so let’s be sure we give them constant doses multiple times a year.  The vaccines were only 52% effective against hospitalization even shortly after vaccination and dropped rapidly within six months.  As usual complete failure to consider prior infection status.  (CDC Article)

On the other hand, and undoubtedly to the despair of the vax safety nuts, a large study under the BEST initiative using massive claims databases, finds little evidence of safety issues in children.  In a study involving over 4 million children, two signals were noted in looking at 15 adverse events–the usual heart inflammation in children 12-17 years old and seizures in children 2 to 5.  The seizure finding was marginal, subject to changes in certain parameters.   (JAMA Article)

This study from England claims to find that vaxed persons are somewhat less likely than unvaxed ones to have the mythical “long” CV-19, but have no less use of health care resources like primary care.  Once more, completely inadequate adjustment for prior infection.  Since the whole notion of extended CV-19 symptoms is questionable, particularly in comparison to lasting symptomology after any serious illness, not sure why people are wasting their time on this topic.  (Medrxiv Paper)

Here is another in the line of research trying to identify if other coronaviruses might prompt cross-reactive antibodies, which regions of the virus are common enough for the immune response to react to new coronaviruses and how the findings might guide future vaccine strategy.  The researchers did find several common regions that certain antibodies reacted against and that have low mutation rates.  (Medrxiv Paper)


Leave a comment